ArticleCancers2022
The Prognostic Value of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma: A Propensity-Matched Study Based on SEER Database.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- The effectiveness of adjuvant radiotherapy after thymoma resection: a systematic review and meta-analysis.World journal of surgical oncology · 2025Pooled it
- Thymoma in the United States (2000-2023): Population-Based Incidence, Treatment Patterns, and Survival.Cureus · 2026Article
- Postoperative radiotherapy improves overall survival and was not associated with a statistically significant increase in cardiac-specific mortality in thymoma patients: a propensity score-matched analysis of the SEER database.Journal of thoracic disease · 2026Article
- Prognostic nomograms for overall and cancer-specific survival in individuals with large cell neuroendocrine carcinoma: a population-based study.Translational cancer research · 2026Article
- Optimising individualised treatment decisions for locally advanced thymoma: precision selection of minimally invasive surgery and postoperative adjuvant radiotherapy.Frontiers in oncology · 2026Review
- Dose and normal tissue complication probability analysis of various radiotherapy regimens for thymomas.Frontiers in oncology · 2026Article
- Postoperative therapy patterns for thymic carcinoma with complete resection: retrospective analysis of 120 patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Machine learning for predicting the prognosis of patients with thymoma and thymic carcinoma.Journal of thoracic disease · 2025Article
- Results of radiotherapy for thymoma: retrospective cohort and propensity score matching analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025Article
- Postoperative radiotherapy after extirpative surgery may not improve survival in patients with Masaoka-Koga stage IIB thymoma: a propensity-matched study based on the SEER database.Journal of thoracic disease · 2024Article
- Postoperative radiotherapy for thymic epithelial tumors: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors.Thoracic cancer · 2023Article
- The role of surgery in advanced thymic tumors: A retrospective cohort study.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
(1) Objectives: The effect of postoperative radiotherapy (PORT) for thymoma and thymic carcinoma remains controversial. This study aimed to investigate the prognostic value of PORT for thymoma and thymic carcinoma in a population-based registry. (2) Methods: This retrospective study used the Surveillance, Epidemiology, and End Results (SEER) database to identify patients diagnosed with thymoma and thymic carcinoma between 2010 and 2019. Propensity score matching was performed to adjust statistical influences between the PORT and non-PORT groups. (3) Results: A total of 2558 patients with thymoma (n = 2138) or thymic carcinoma (n = 420) were included. In the multivariate analysis, PORT was an independent prognostic factor for OS (overall survival; p < 0.001) and CSS (cancer-specific survival; p = 0.001) in thymoma and an independent prognostic factor for OS in thymic carcinoma (p = 0.018). Subgroup analyses revealed that PORT was beneficial to OS and CSS in patients with Masaoka-Koga stage IIB-IV thymoma (OS: IIB, p < 0.001; III-IV, p = 0.005; CSS: IIB, p = 0.015; III-IV, p = 0.002) and stage IIB thymic carcinoma (OS: p = 0.012; CSS: p = 0.029). (4) Conclusion: This propensity-matched analysis identified the prognostic value of PORT in thymoma and thymic carcinoma based on the SEER database. For patients with stage IIB-IV thymoma and stage IIB thymic carcinoma, PORT was associated with improved OS and CSS. A more positive attitude towards the use of PORT for nonlocalized thymoma and thymic carcinoma may be appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.